tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Meiser BM and Reichart B New trends in clinical immunosuppression. 1994 Transplant. Proc. pmid:7527954
Christe W Neurological disorders in liver and kidney transplant recipients. 1994 Transplant. Proc. pmid:7527953
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Mueller AR et al. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. 1994 Transplant. Proc. pmid:7527951
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Lea JP et al. Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin. 1994 Kidney Int. pmid:7527873
Cooper MH et al. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. 1994 Bone Marrow Transplant. pmid:7527689
Abdalla AH et al. FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. 1994 Transpl. Int. pmid:7527640
Stark JH et al. Sensitivity of baboon lymphocytes to cyclosporin A and FK 506: relative resistance of alloactivated cells to CyA. 1994 Transpl. Int. pmid:7527639
Winkler M et al. The use of plasma levels for FK 506 dosing in liver-grafted patients. 1994 Transpl. Int. pmid:7527638
Jiang H et al. The superior effect of the combination of FK 506 and deoxyspergualin on rat cardiac allograft survival. 1994 Transpl. Int. pmid:7527637
Calmus Y [Rejection of a liver allograft. Diagnosis and treatment]. 1994 Ann Radiol (Paris) pmid:7527621
Chen SR et al. Asymmetrical blockade of the Ca2+ release channel (ryanodine receptor) by 12-kDa FK506 binding protein. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7527548
Lewis HM Therapeutic progress. II: Treatment of psoriasis. 1994 J Clin Pharm Ther pmid:7527403
Winkler M et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. 1994 Clin. Chem. pmid:7527306
Shaw LM and Brayman KL FK-506 therapeutic drug monitoring. 1994 Clin. Chem. pmid:7527305
Rosenwirth B et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. 1994 Antimicrob. Agents Chemother. pmid:7527198
Alnemri ES et al. FKBP46, a novel Sf9 insect cell nuclear immunophilin that forms a protein-kinase complex. 1994 J. Biol. Chem. pmid:7527037
Lemoine A et al. FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation. 1994 Hepatology pmid:7527003
Akamine S et al. Monitoring canine lung allograft rejection using Ia antigen expression by bronchoalveolar lymphocytes. 1994 Surg. Today pmid:7526914
Bush KT et al. Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. 1994 Biochem. J. pmid:7526846
Lauerma AI et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. 1994 Arch. Dermatol. Res. pmid:7526805
Carroll PB et al. Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results. 1994 Arch Dermatol pmid:7526802
Ishioka M et al. FK506 treatment of noninfectious uveitis. 1994 Am. J. Ophthalmol. pmid:7526689
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Radanyi C et al. The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7526392
Connolly JO et al. Renal arteriopathy associated with FK 506 therapy following liver transplantation. 1994 Nephrol. Dial. Transplant. pmid:7526278
Cullen BR and Heitman J Human immunodeficiency virus. Chaperoning a pathogen. 1994 Nature pmid:7526224
Kinoshita I et al. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. 1994 Muscle Nerve pmid:7526208
Hacker J and Fischer G Immunophilins: structure-function relationship and possible role in microbial pathogenicity. 1993 Mol. Microbiol. pmid:7526121
Hiromatsu Y et al. Inhibitory effect of FK506 on intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells. 1994 Kurume Med J pmid:7526029
Mukaida N et al. Molecular mechanism of interleukin-8 gene expression. 1994 J. Leukoc. Biol. pmid:7525815
Funk JO and Maibach HI Horizons in pharmacologic intervention in allergic contact dermatitis. 1994 J. Am. Acad. Dermatol. pmid:7525668
Gruber SA et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. 1994 J Clin Pharmacol pmid:7525661
Benton BM et al. A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus. 1994 J. Cell Biol. pmid:7525596
Shafiee A et al. Enzymology of FK-506 biosynthesis. Purification and characterization of 31-O-desmethylFK-506 O:methyltransferase from Streptomyces sp. MA6858. 1994 Eur. J. Biochem. pmid:7525282
Tamir H et al. Secretogogue-induced gating of chloride channels in the secretory vesicles of parafollicular cells. 1994 Endocrinology pmid:7525261
Milan D et al. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. 1994 Cell pmid:7525078
Papaccio G et al. The immunosuppressant FK506 inhibits the damage to mouse pancreatic islets induced by low dose streptozocin. 1994 Cell Tissue Res. pmid:7525068
von Asmuth EJ et al. IL-6, IL-8 and TNF production by cytokine and lipopolysaccharide-stimulated human renal cortical epithelial cells in vitro. 1994 May-Jun Eur. Cytokine Netw. pmid:7524716
Yu L and Fesik SW pH titration of the histidine residues of cyclophilin and FK506 binding protein in the absence and presence of immunosuppressant ligands. 1994 Biochim. Biophys. Acta pmid:7524680
Lepre CA et al. Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12. 1994 Biochemistry pmid:7524662
Bierer BE Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action. 1994 Chem. Immunol. pmid:7524531
Burnett D et al. Inhibition by FK506 of formyl peptide-induced neutrophil activation and associated protein synthesis. 1994 Biochem. Pharmacol. pmid:7524504
Przepiorka D et al. Blood tacrolimus concentration unchanged by plasmapheresis. 1994 Am J Hosp Pharm pmid:7524318
Tacrolimus introduced for use in liver transplantation. 1994 Am J Hosp Pharm pmid:7524317
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
Kattner A et al. Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA malabsorption. 1994 Transplant. Proc. pmid:7524225
Kupferman JC et al. Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. 1994 Transplant. Proc. pmid:7524224
Yoshimura R et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7524223
Heitman J et al. Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 1994 Transplant. Proc. pmid:7524220
Takahara S et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. 1994 Transplant. Proc. pmid:7524219
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
FDA approved new drug bulletin: aprotinin injection (trasylol), tacrolimus (prograf). 1994 RN pmid:7524131
Perotti BY et al. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. 1994 Pharm. Res. pmid:7524055
Schleuning M et al. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. 1994 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7523957
Calne RY Immunosuppression in liver transplantation. 1994 N. Engl. J. Med. pmid:7523947
A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. 1994 N. Engl. J. Med. pmid:7523946
Schmidt A et al. Two FK506 resistance-conferring genes in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid permeases mediating tyrosine and tryptophan uptake. 1994 Mol. Cell. Biol. pmid:7523855
Collins RH Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523807
Krentz AJ et al. Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523806
Moore R and Lord R Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523805
Ohtomo Y et al. Coexisting NPY and NE synergistically regulate renal tubular Na+, K(+)-ATPase activity. 1994 Kidney Int. pmid:7523751
Hiromura K et al. FK506 inhibits renal glomerular thrombosis induced in rats by nephrotoxic serum and lipopolysaccharide. 1994 Kidney Int. pmid:7523750
Karmann K et al. Endothelial cell-induced resistance to cyclosporin A in human peripheral blood T cells requires contact-dependent interactions involving CD2 but not CD28. 1994 J. Immunol. pmid:7523510
Clipstone NA et al. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. 1994 J. Biol. Chem. pmid:7523407
Kay AB Immunosuppressive agents in chronic severe asthma. 1994 May-Jun Allergy Proc pmid:7523242
Ahern GP et al. Single channel activity of the ryanodine receptor calcium release channel is modulated by FK-506. 1994 FEBS Lett. pmid:7523191
Hakamata Y et al. Involvement of the brain type of ryanodine receptor in T-cell proliferation. 1994 FEBS Lett. pmid:7523185
Schmidt B et al. A homodimer represents an active species of the peptidyl-prolyl cis/trans isomerase FKBP25mem from Legionella pneumophila. 1994 FEBS Lett. pmid:7523184
Pai SY et al. Cross-linking CD28 leads to activation of 70-kDa S6 kinase. 1994 Eur. J. Immunol. pmid:7523138
Moia LJ et al. Immunosuppressants and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdaloid kindled rat. 1994 Brain Res. pmid:7522929
Shapiro R et al. Improving results of pediatric renal transplantation. 1994 J. Am. Coll. Surg. pmid:7522851
Abu-Elmagd K et al. Three years clinical experience with intestinal transplantation. 1994 J. Am. Coll. Surg. pmid:7522850
Mouzaki A and Rungger D Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated or drug-treated naive and memory T-helper cells. 1994 Blood pmid:7522636
Abu-Elmagd K et al. Recent advances in hepatic transplantation at the University of Pittsburgh. 1993 Clin Transpl pmid:7522528
Lebeau MC et al. Rabbit FKBP-59/HBI does not inhibit calcineurin activity in vitro. 1994 Biochem. Biophys. Res. Commun. pmid:7522447
Todo S et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. 1994 Ann. Surg. pmid:7522431
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
Bram RJ and Crabtree GR Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. 1994 Nature pmid:7522304
Sharkey J and Butcher SP Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. 1994 Nature pmid:7522303
Nakagawa H et al. Tacrolimus ointment for atopic dermatitis. 1994 Lancet pmid:7522297
Nichols RA et al. Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. 1994 J. Biol. Chem. pmid:7522234
Metcalfe S et al. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. 1994 Cell. Immunol. pmid:7522130
Jung-Testas I et al. [Inhibition of the anti-glucocorticosteroid effect of RU486 on the growth of mouse fibroblasts in culture by the immunosuppressor kf506]]. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522119
Renoir JM et al. Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522118
D'Ambrosio R et al. Multicenter comparison of tacrolimus (FK 506) whole blood concentrations as measured by the Abbott IMX analyzer and enzyme immunoassay with methylene chloride extraction. 1994 Ther Drug Monit pmid:7521979
Winkler M et al. Comparison of different assays for the quantitation of FK 506 levels in blood or plasma. 1994 Ther Drug Monit pmid:7521978
Jensen C et al. Interaction between tacrolimus and erythromycin. 1994 Lancet pmid:7521928
Krentz AJ et al. Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506. 1994 J. Lab. Clin. Med. pmid:7521895